I
Intracellular Therapies
Therapeutics for central nervous system disorders
About Intracellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and neurologic disorders. The company operates in the healthcare sector, targeting patients suffering from conditions such as schizophrenia and bipolar depression. Its flagship product, CAPLYTA, is an FDA-approved medication designed to address these mental health issues. The company serves healthcare providers, patients, and caregivers, aiming to improve the quality of life for individuals affected by these disorders.
Intra-Cellular Therapies employs a business model centered around the discovery, development, and commercialization of novel therapeutics. Revenue is primarily generated through the sale of CAPLYTA and other investigational compounds in their pipeline. The company leverages its extensive expertise in drug development to bring new treatments from the research phase to market readiness.
Key markets include the United States and other regions with significant demand for advanced neuropsychiatric treatments. The company continuously invests in research and development to expand its portfolio and address unmet medical needs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Open roles
Intracellular Therapies in the New York City ecosystem
The Intracellular Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A1 investor entered at this stage
- ACAlafi Capital
Series B and later1 investor entered at this stage
- TVTech Council Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intracellular Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intracellular Therapies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



J&J acquires Intra-Cellular (April 2025)
